SEP - 5 2003

K031938 (p.1 of 2)

510(k) SUMMARY OF SAFETY AND EFFECTIVENESS

This 510(k) summary of safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and CFR 807.92

1. SUBMITTER INFORMATION

a. Company Name:	SenoRx Inc.
b. Company Address:	11 Columbia, Suite A
c. Telephone: Facsimile:	(949) 362-4800 (949) 362-3519
d. Contact Person:	Amy Boucly Director, Regulatory Affairs and Quality Assurance
e. Date Summary Prepared:	June 12, 2003

2. DEVICE IDENTIFICATION

a. Trade/Proprietary Name:	Gel Mark III (Trade Name is to be determined.)
b. Classification Name:	Implantable Staple, 21 CFR 878.4750

3. IDENTIFICATION OF PREDICATE DEVICES

Gel Mark™ Biopsy Site Marker	SenoRx Inc.
Gel Mark™ Ultra Biopsy Site Marker	SenoRx Inc.
MammoMark™ Biopsy Site Marker	Artemis Medical, Inc.

K031938 (p. 2 of 2)

4. DESCRIPTION OF THE DEVICE

The SenoRx Gel Mark III consists of a disposable applicator containing resorbable pellets. Some pellets contain a wireform, which is intended for long-term marking of the biopsy cavity.

5. STATEMENT OF INTENDED USE

The Gel Mark III is intended to radiographically mark breast tissue during a percutaneous breast biopsy procedure.

6. COMPARISON WITH PREDICATE DEVICES

The intended use, design, construction, marker material and nominal specifications are similar to the predicate devices.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

SEP - 5 2003

Ms. Amy Boucly
Director, Regulatory Affairs
and Quality Assurance
SenoRx, Inc.
11 Columbia, Suite A.
Aliso Viejo, California 92656

Re: K031938
Trade/Device Name: Gel Mark III Biopsy Site Marker
Regulation Number: 21 CFR 878.4300
Regulation Name: Implantable Clip
Regulatory Class: II
Product Code: NEU
Dated: June 20, 2003
Received: June 23, 2003

Dear Ms. Boucly:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Miriam C. Provost

for Celia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

2 FDA Indications for Use Page

510(k) number (if known): K031938

Device Name: Gel Mark III (Trade/Model Name to be determined.)

Indications for Use: The Gel Mark III is indicated for use to radiographically mark breast tissue during a percutaneous breast biopsy procedure.

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use X OR Over-The-Counter Use _____
(Per 21 CFR 801.109)

Miriam C. Provost
(Division Sign-Off)
Division of General, Restorative and Neurological Devices

510(k) Number K031938